Prevalence of sarcopenia using different methods in patients with non-alcoholic fatty liver disease

Table 3 Association of sarcopenia with the classification of body mass index, degrees of steatosis and presence of fibrosis (Pearson's chi-square test)

		EWGSOP1				EWGSOP2
Variable		No Sarcopenia, n = 54	Pre-sarcopenia, n = 1	Sarcopenia, n = 2	P value	No sarcopenia, n = 42	Probable sarcopenia, n = 15	P value
BMI, n (%)
No excess weight		7 (13.0)	0 (0.0)	2 (100.0)	0.003	6 (14.3)	3 (20.0)	0.685
Overweight		47 (87.0)	1 (100.0)	0 (0.0)		36 (85.7)	12 (80.0)
Degree of steatosis, n (%)
Grade I		18 (33.3)	1 (100.0)	2 (100.0)	0.027	17 (40.5)	4 (26.7)	0.534
Grade II-III		36 (66.7)	0 (0.0)	0 (0.0)		25 (59.5)	11 (73.3)
FIB-41
No fibrosis		49 (96.1)	1 (100.0)	2 (100.0)	0.740	38 (97.4)	14 (93.3)	0.484
Fibrosis		2 (3.9)	0 (0.0)	0 (0.0)		1 (2.6)	1 (6.7)
APRI1
No fibrosis		42 (82.4)	1 (100.0)	2 (100.0)	0.448	33 (84.6)	12 (80.0)	0.688
Fibrosis		9 (17.6)	0 (0.0)	0 (0.0)		6 (15.4)	3 (20.0)

¹n = 54, considering three patients who did not have biochemical tests.

EWGSOP1: European Working Group of Sarcopenia in Older People, 2010; EWGSOP2: European Working Group of Sarcopenia in Older People, 2018; BMI: Body mass index; FIB-4: Fibrosis-4 index; APRI: Aspartate aminotransferase to platelet ratio index.